Skip to content
mesothelioma chemotherapy

Mesothelioma Chemotherapy Journal Articles

Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma.

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial

Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability

A randomised trial in malignant mesothelioma of early versus delayed chemotherapy in symptomatically stable patients: the MED trial.

Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia

Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma.

Malignant Mesothelioma Continues to Present a Difficult Therapeutic Target - ASCO report

The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.

Positron emission tomography predicts survival in malignant pleural mesothelioma.

Gene therapy for malignant mesothelioma: beyond the infant years.

Multimodality approach in management of malignant pleural mesothelioma.

Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations

Physical and chemical stability of pemetrexed in infusion solutions.

Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma

Prognostic factors in mesothelioma

Thalidomide in patients with malignant pleural mesothelioma.

The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.

Novel Complimentary Therapies Boost Role of Surgery for Mesothelioma Cancer

Chemotherapy for malignant pleural mesothelioma: past results and recent developments

Chemotherapy options and new advances in malignant pleural mesothelioma.

Assessing quality of life during chemotherapy for pleural mesothelioma

Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

Pemetrexed in combination with cisplatin in the treatment of chemonaive patients with malignant pleural mesothelioma (MPM)

A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma

Pemetrexed alone or in combination with cisplatin in the treatment of patients with peritoneal mesothelioma (PM)

Pemetrexed therapy for malignant pleural mesothelioma.

The evolving role of pemetrexed (Alimta) in lung cancer

Overview of phase I/II pemetrexed studies.

Irinotecan for malignant mesothelioma

Raltitrexed–Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients

Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma.

Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Homocysteine and Methylmalonic Acid: Markers to Predict and Avoid Toxicity from Pemetrexed Therapy

Interferon Alpha May Help Treat Malignant Pleural Mesothelioma

Xenavex

Ribonucleases as a Novel Pro-Apoptotic Anticancer Strategy

Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin.

Trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.

Effect of N-terminal and Met23 mutations on the structure and dynamics of onconase.

A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II–III malignant pleural mesothelioma

A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: Outcomes of an expanded access program

Activation of Caspases and Serine Proteases during Apoptosis Induced by Onconase

Cancer and bacteria

Many experts say that germs have the ability to make the body adjust and learn about the fighting back mechanism against tumors.

A Pill Card for keeping track of your meds

molecular diagram   This is a Microsoft Word document developed at the Agency for Healthcare Research and Quality. We like it.

 

 

If you have mesothelioma, we might be able to help you. Fill out this form.

Your Question or Comment:
Name:
Phone Number:
E-mail:
Street Address:
City, State, Zip:
**(Packet includes information on treatment, clinical trials, cancer links, how to access legal and financial resources, and frequently asked legal questions with answers provided by The David Law Firm, P.C.). By filling out the above form you consent to being contacted by The David Law Firm regarding potentially retaining legal services.

This website is sponsored by Jonathan David* of The David Law Firm. The David Law Firm is located in The Woodlands, Texas (Greater Houston Area) and can be reached toll free at 1-800-998-9729 for more information on mesothelioma. Jonathan David is not a medical doctor. The information on these pages is for the education of mesothelioma patients and their families regarding potential medical and legal options. Patients are advised to consult with a medical doctor.

*  Licensed by the Supreme Court  of Texas.

 

 

 

The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a clinical practice guideline.

Advances in the systemic therapy of malignant pleural mesothelioma

Kinase Inhibitors for Mesothelioma Treatment

journal abstracts

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial

The second wave in kinase cancer drugs

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma


Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma.